The Baseline platform enables better and faster clinical trial execution, improved data aggregation and analysis, flexible study options designed for decentralized and hybrid trials, and the ability to capture real-world data, such as that generated by novel sensors and biomarkers
Verily, an Alphabet company, today announced that its previously announced acquisition of SignalPath, a privately held company that makes clinical research software based in Raleigh, has successfully closed.
The acquisition will strengthen and expand Verily’s existing clinical trial system and evidence generation platform, known as Baseline. The Baseline platform enables better and faster clinical trial execution, improved data aggregation and analysis, flexible study options designed for decentralized and hybrid trials, and the ability to capture real-world data, such as that generated by novel sensors and biomarkers.
The SignalPath clinical trials management system (CTMS) brings state-of-the-art software to clinical research sites that improves the ease, quality and efficiency of conducting clinical research.
“Joining forces helps us to accelerate our shared ambition to make clinical research work better for everyone involved, and get medicines and devices to patients more quickly,” said Amy Abernethy, MD, PhD, President of Clinical Studies Platforms at Verily. “Together, we’ll bring more comprehensive and digital solutions to the clinical trial ecosystem and modernize the way clinical research is conducted.”
SignalPath co-founder and CEO Brad Hirsch, MD, and his leadership team will remain with the company and continue their work. The company’s approximately 100 employees will join Verily as part of Verily’s clinical research business. SignalPath will remain in its current Raleigh location, drawing on the abundance of healthcare and technology talent in the Triangle, and increasing Verily’s footprint with a new location in North Carolina.
Source: Company Press Release